Product Description
Alicaforsen, a 20 base ICAM-1 anti-sense oligonucleotide and highly selective ICAM-1 inhibitor, down-regulates ICAM-1 mRNA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28670932/)
Mechanisms of Action: ICAM-1 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ionis
Company Location: CARLSBAD CA 92010
Company CEO: Brett P. Monia
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Crohn Disease|Pouchitis
Phase 2: Colitis, Ulcerative
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Study to compare Alicaforsen with placebo in patients with Pouchitis | P3 |
Completed |
Pouchitis |
2019-01-18 |
|
| ACH UCP-301 | P3 |
Completed |
Pouchitis |
2018-07-09 |
|
| ACH HV-AO-101 | P1 |
Completed |
Healthy Volunteers |
2018-04-06 |
28% |
| ISIS 2302-CS22 | P2 |
Completed |
Colitis, Ulcerative |
2005-03-24 |